Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Anakinra prevents high glucose-mediated potentiation of IL-1β-induced NLRP3 inflammasome activation, small extracellular vesicle release and vascular inflammation.

Biochemical pharmacology·2026
Same author

Hypertension in autoimmune rheumatic diseases: a position paper from the European Society of Hypertension working group on small arteries. Part A: pathophysiology, prevalence and cardiovascular risk estimation.

Journal of hypertension·2026
Same author

Hypertension in autoimmune rheumatic diseases - a position paper from the European Society of Hypertension working group on small arteries. Part B: Recommendations for the clinical management of hypertension.

Journal of hypertension·2026
Same author

Primary cilia disruption reprograms extracellular vesicle signaling in endothelial dysfunction and cardiovascular disease.

Life sciences·2026
Same author

Simtuzumab Attenuates Loxl2-Mediated Extracellular Matrix Remodeling and Preserves Cardiac Function in <i>LMNA</i> Mutation-Induced Dilated Cardiomyopathy.

Circulation. Heart failure·2026
Same author

Amyloid-beta (1-40) peptide is associated with systemic metabolic health.

European journal of clinical investigation·2026

Related Experiment Video

Updated: Jun 14, 2026

Hemodynamic Characterization of Rodent Models of Pulmonary Arterial Hypertension
09:40

Hemodynamic Characterization of Rodent Models of Pulmonary Arterial Hypertension

Published on: April 11, 2016

Circulating microparticles from pulmonary hypertensive rats induce endothelial dysfunction.

Simon Tual-Chalot1, Christelle Guibert, Bernard Muller

  • 1CNRS UMR 6214, Faculté de Médecine, Rue Haute de Reculée, Angers, F-49045 France.

American Journal of Respiratory and Critical Care Medicine
|March 27, 2010
PubMed
Summary

Hypoxic microparticles (MPs) increase in pulmonary arterial hypertension (PAH), causing endothelial dysfunction by reducing nitric oxide (NO) production. These MPs show tissue specificity, increasing oxidative stress only in pulmonary endothelial cells.

More Related Videos

Shunt Surgery, Right Heart Catheterization, and Vascular Morphometry in a Rat Model for Flow-induced Pulmonary Arterial Hypertension
09:23

Shunt Surgery, Right Heart Catheterization, and Vascular Morphometry in a Rat Model for Flow-induced Pulmonary Arterial Hypertension

Published on: February 11, 2017

Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis
07:11

Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis

Published on: May 23, 2025

Related Experiment Videos

Last Updated: Jun 14, 2026

Hemodynamic Characterization of Rodent Models of Pulmonary Arterial Hypertension
09:40

Hemodynamic Characterization of Rodent Models of Pulmonary Arterial Hypertension

Published on: April 11, 2016

Shunt Surgery, Right Heart Catheterization, and Vascular Morphometry in a Rat Model for Flow-induced Pulmonary Arterial Hypertension
09:23

Shunt Surgery, Right Heart Catheterization, and Vascular Morphometry in a Rat Model for Flow-induced Pulmonary Arterial Hypertension

Published on: February 11, 2017

Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis
07:11

Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis

Published on: May 23, 2025

Area of Science:

  • Cardiovascular Research
  • Endothelial Biology
  • Pulmonary Hypertension

Background:

  • Pulmonary arterial hypertension (PAH) involves increased pulmonary vascular resistance and arterial remodeling.
  • Microparticles (MPs) are implicated as vectors of endothelial dysfunction in various diseases.

Purpose of the Study:

  • Characterize circulating MPs in hypoxic PAH models.
  • Investigate the impact of MPs on endothelial function.

Main Methods:

  • Rats exposed to chronic hypoxia to induce PAH.
  • Characterization of normoxic and hypoxic MPs via flow cytometry.
  • In vitro incubation of endothelial cells (ECs) with MPs.
  • Analysis of nitric oxide (NO) and reactive oxygen species (ROS) pathways.
  • In vivo assessment of endothelium-dependent relaxation.

Main Results:

  • Hypoxic rats exhibited a twofold increase in circulating MPs.
  • MPs from hypoxic rats reduced NO production in aortic and pulmonary ECs by enhancing eNOS phosphorylation.
  • Hypoxic MPs elevated oxidative stress specifically in pulmonary ECs via xanthine oxidase and mitochondrial pathways.
  • In vivo administration of hypoxic MPs impaired endothelium-dependent relaxation in both aorta and pulmonary arteries.

Conclusions:

  • Circulating MPs in hypoxic PAH induce endothelial dysfunction by decreasing NO bioavailability.
  • MPs exhibit tissue specificity, exacerbating oxidative stress predominantly in pulmonary ECs.
  • These findings highlight MPs as key players in PAH-associated endothelial dysfunction.